ReviewPediatric hematology and oncology2011
Hodgkin disease and the role of the immune system.
Review in Pediatric hematology and oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence.Journal of global health · 2020Pooled it
- Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma.International journal of molecular sciences · 2020Trial
- Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.International journal of surgical pathology · 2026Article
- Review
- Body Composition at Diagnosis and Early Response in Pediatric Hodgkin Lymphoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin's Lymphoma: A Case Report and Review of the Literature.Journal of clinical medicine · 2024Review
- Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging.Pediatric radiology · 2024Article
- Role of non-chromosomal birth defects on the risk of developing childhood Hodgkin lymphoma: A Children's Oncology Group study.Pediatric blood & cancer · 2024Article
- Chronic diarrhoea and ichthyosis vulgaris: a rare presentation of Hodgkin's lymphoma.BMJ case reports · 2024Article
- Screening Strategies for COVID-19 in Patients With Hematologic Malignancies.Frontiers in oncology · 2020Article
- Epstein-Barr virus load is higher in long-term Hodgkin lymphoma survivors compared to their unaffected twins and unrelated controls.British journal of haematology · 2019Article
- Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?Oncology (Williston Park, N.Y.) · 2016Review
- Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- A difficult diagnosis of Hodgkin lymphoma due to immune thrombocytopenia.Clinical case reports · 2015Article
- Article
- FAS system deregulation in T-cell lymphoblastic lymphoma.Cell death & disease · 2014Article
- Targeting two co-operating cytokines efficiently shapes immune responses.Oncoimmunology · 2013Article
- Article
- Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hodgkin disease (HD) is a malignancy of primarily B lymphocytes that has the unique ability to cause immunodeficiency, as well as provide immune evasion mechanisms to avoid self-destruction. In this review, the authors discuss Hodgkin disease, its association with Epstein-Barr virus (EBV), the immune deficiency caused by HD, and tumor immune evasion mechanisms. Specifically, the authors closely evaluate the roles of regulatory T cells in HD, cytotoxic T cells, cytokine and chemokine secretion, down-regulation of Fas ligand, and indoleamine 2,3-dioxygenase (IDO) secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.